MC4R-selective melanocortin agonism acting on central arousal pathways.
What was measuredRECONNECT trials in premenopausal women with hypoactive sexual desire disorder: statistically significant but modest effect on desire and distress scores.
Also known as Bremelanotide · developed by Palatin / AMAG
Licensed by at least one major regulator for a specific indication, on the strength of completed phase 3 trials. Approval is for that indication in that population — it is not a general endorsement of the compound.
The des-amide metabolite of Melanotan II, developed separately as a melanocortin agonist for sexual dysfunction. The two compounds differ by one functional group, and that difference produced one approved medicine and one regulators warn against.
Melanocortin receptor agonist with relative MC4R selectivity, acting centrally on pathways involved in sexual arousal rather than on vascular tissue as PDE5 inhibitors do.
The RECONNECT trials in premenopausal women with HSDD showed statistically significant improvement in desire and reduction in distress versus placebo. Approved by the FDA in 2019.
The improvements, while statistically significant, were small in absolute terms — a point made in regulatory review and in subsequent commentary.
This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.
FDA-approved, prescription-only. Not licensed in the UK or EU.
The sites below are where PT-141 is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.
Drag to turn · tap an organ
MC4R-selective melanocortin agonism acting on central arousal pathways.
What was measuredRECONNECT trials in premenopausal women with hypoactive sexual desire disorder: statistically significant but modest effect on desire and distress scores.
Acts centrally rather than on vascular tissue, unlike PDE5 inhibitors.
What was measuredThe mechanism is central by design. It does not produce erection through vasodilation, and was not trialled for that.
This site publishes summaries of published research. It is not medical advice, and Genexis Health does not sell or supply any compound described here. Please confirm each statement below to continue.
We ask everyone to confirm they understand this site is information rather than medical advice before reading it. Because you have not confirmed those statements, you cannot continue.
If you are looking for health advice or treatment, please speak to a licensed healthcare professional. Nothing on this site is a substitute for that.